Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies by Lüthi, François et al.
ORIGINAL ARTICLE
Home care—a safe and attractive alternative to inpatient
administration of intensive chemotherapies
François Lüthi & Nadia Fucina & Nathalie Divorne & Brigitte Santos-Eggimann &
Christine Currat-Zweifel & Patricia Rollier & Jean-Blaise Wasserfallen &
Nicolas Ketterer & Serge Leyvraz
Received: 26 July 2010 /Accepted: 20 February 2011 /Published online: 8 March 2011
# Springer-Verlag 2011
Abstract
Objective The objective of this study was to evaluate
feasibility, safety, perception, and costs of home care for
the administration of intensive chemotherapies.
Methods Patients receiving sequential chemotherapy in an
inpatient setting, living within 30 km of the hospital, and
having a relative to care for them were offered home care
treatment. Chemotherapy was administered by a portable,
programmable pump via an implantable catheter. The main
endpoints were safety, patient’s quality of life [Functional
Living Index—Cancer (FLIC)], satisfaction of patients and
relatives, and costs.
Results Two hundred days of home care were analysed,
representing a total of 46 treatment cycles of intensive
chemotherapy in 17 patients. Two cycles were complicated
by technical problems that required hospitalisation for a
total of 5 days. Three major medical complications (heart
failure, angina pectoris, and major allergic reaction) could
be managed at home. Grades 1 and 2 nausea and vomiting
occurring in 36% of patients could be treated at home.
FLIC scores remained constant throughout the study. All
patients rated home care as very satisfactory or satisfactory.
Patient benefits of home care included increased comfort
and freedom. Relatives acknowledged better tolerance and
less asthenia of the patient. Home care resulted in a 53%
cost benefit compared to hospital treatment (€420±120/day
vs. €896±165/day).
Conclusion Administration of intensive chemotherapy
regimens at home was feasible and safe. Quality of life was
not affected; satisfaction of patients and relatives was very
high. A psychosocial benefit was observed for patients and
relatives. Furthermore, a cost–benefit of home care compared
to hospital treatment was demonstrated.
Keywords Home care . Quality of life . Satisfaction .
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Introduction
The main goals of home care treatment are to provide state-
of-the-art patient care, improve convenience, and reduce the
burden on healthcare systems.
Home care treatment has been investigated in different
non-oncologic conditions and following certain medical
procedures [1–6]. Studies often focused on elderly patients
admitted for elective procedures or age-related diseases.
Home care was associated with significantly shorter
hospital stays, fewer geriatric complications, and did not
increase the rate of subsequent readmissions [4, 6]. Patients
and care giving relatives reported high levels of satisfaction
following home care treatment [1, 4]. A meta-analysis of 22
trials revealed a decreased mortality and readmission rates
in elderly patients receiving home care compared with
hospital care patients [4].
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In oncology, the majority of home care programs have
focused on supportive care or the administration of standard
chemotherapy regimens. Intensive and potentially toxic
chemotherapies are still given on an inpatient basis and
have never been administered at home. Home care has been
successful in patients following chemotherapy and stem cell
transplantation without increasing the risk of toxicity or
infection [7–10]. Furthermore, in pediatric oncology, home
care has been shown to be effective and safe and had
additional psychosocial benefits for both children and
caring parents [11–13].
Since management of chemotherapy-related side effects
has improved and new, safe treatment schedules, and
administration tools have been introduced [13–15], home
care is becoming a valid alternative to hospital-based
treatment of oncology patients.
There is evidence suggesting that home care treatment of
oncology patients can reduce costs in comparison to
inpatient care [16, 17]. A conclusive cost comparison
depends on the way costs are calculated [4]. Nevertheless,
a recent study exploring UK National Health Services and
published data on home-based chemotherapy illustrated that
cost-related information is often difficult to gather, incom-
plete (e.g., lack of indirect costs), or of poor quality [18].
Accordingly, the authors concluded that more feasibility
studies are warranted.
In the current study, our objective was to evaluate the
feasibility and safety of home administration of intensive
chemotherapy regimens that are usually recommended to be
administered in an inpatient facility. Quality of life and the
satisfaction of patients and their relatives with home care
were also assessed. Furthermore, the costs of home and
inpatient treatment were compared in a subgroup of patients
who received similar treatments in both settings.
Patients and methods
Patients
Eligible patients had to be 16 years or older, assigned to one of
the intensive chemotherapy treatments listed in Table 1, and
fitted with a central venous catheter to qualify for inclusion
in the study. Furthermore, patients were required to live
within 30 km of the hospital and with a relative who had
given consent to be the named care giver during the study.
Main exclusion criteria were poor performance status
(ECOG≥2) and severe cardiac, lung, or renal co-morbidities.
The study protocol was approved by the ethical
committee of the University Hospital, Lausanne and was
carried out in compliance with good clinical practice
guidelines. Written consent was obtained from patients
prior to inclusion in the trial. The patients had the right to
withdraw from the study at any time. In addition, patients
could be withdrawn from the study upon request of the
caring relative.
Treatment
The studied chemotherapy regimens were intensive treat-
ments currently given on a hospital inpatient basis (Table 1).
The treatment was administered through a portable,
programmable pump with four entrance and two exit
channels, allowing multiple infusion modes (Melodie®,
Aguettant, Lyon, France). All chemotherapy agents used in
the study were approved for the specific indication and
easily administered through a programmable pump and
known to be stable in syringes. Additional treatments, such
as anti-emetics, anxiolytics, corticosteroids, diuretics, and
methylene blue, were administered according to standard
inpatient practices. Hydration was also controlled by the
pump. Blood transfusions or hematopoietic stem cell
reinfusion had to be administered in the hospital if needed.
A medical team consisting in a trained oncology nurse
and a medical oncologist took care of the patients during
the study. The nurse was responsible for standard nursing
care and vital signs monitoring, preparation of chemother-
apy (together with the hospital central pharmacy), and
organisation of the home care and treatment administration.
Patients were monitored during planned visits by the nurse
(twice daily) and the medical oncologist (once daily).
Patients could reach the medical team at any time via a
24 h, 7 days a week call service.
Feasibility
Mechanical and software problems relating to pump
function and information on other logistical problems were
recorded by the nurse.
Safety
Safety aspects were assessed and recorded by the medical
oncologist [19]. Major complications during home care
were defined as toxicity (WHO>2, except for gastrointes-
tinal toxicity), uncontrolled vomiting or nausea, renal
failure with oliguria, inpatient hospitalisation due to febrile
episode or vital symptom modification (hemodynamic
instability, cardiac pulse arrhythmia, respiratory distress,
and CNS disturbances), and hospitalisation upon request of
patient or relative.
Quality of life
Quality of life was assessed by the ‘Functional Living
Index—Cancer’ (FLIC) questionnaire [20] that was com-
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Table 1 Chemotherapy regimens and treatment cycles administered at home
Treatment Cycles (n) Treatment days (n)
Standard ICEa 10 30
Ifosfamide and uromitexan (each 5 g/m2, IV over 24 h), carboplatin
(300 mg/m2, IV on day 1), etoposide (180 mg/m2/day, IV on days 1+2);
total treatment duration: 3 days
High-dose ifosfamide-adriamycineb 8 56
Ifosfamide (2 gm−2 day−1, IV over 5 days), adriamycine (30 mg/m2,
IV on days 1–3), uromitexan (2 gm−2 day−1, IV on days 1–6);
total treatment duration: 7 days
BEACOPPc 7 21
Cyclophosphamide (650 mg/m2, IV on day 1), adriamycine
(25 mg/m2, IV on day 1), etoposide (100 mg/m2, IV on days 1–3);
total treatment duration: 3 days
Ara-C-cyclophosphamided 5 10
Ara-C (500 mg/m2, IV on day 1), cyclophosphamide
(1 g/m2, PO on day 1); total treatment duration: 2 days
VADe 4 20
Vincristine and adriamycine (0.4 mg/day and 9 mg m−2 day−1,
IV over 4 days), dexamethasone (40 mg PO on days 1–4);
total treatment duration: 5 days
Standard ifosfamide-adriamycinf 3 21
Ifosfamide and uromitexan (5 g/m2 and 6 g/m2, IV over 24 h),
adriamycine (75 mg/m2, IV on day 1); total treatment duration: 3 days
MINEg 2 14
Mitoguazone (500 mg/m2, IV on days 1+2), ifosfamide and uromitexan
(1.5 gm−2 day−1 and 1.5 g/m2/day, IV over 5 days), etoposide
(150 mg m−2 day−1, PO on days 1–3), navelbine (15 mg m−2 day−1,
PO on days 1+2); total treatment duration: 7 days
BEAMh 2 14
BCNU (300 mg/m2, IV on day 1), etoposide (200 mg m−2 day−1,
IV on days 2–5), AraC (200 mg m−2 day−1, IV on days 2–5),
melphalan (140 mg/m2, IV on day 6); total treatment duration: 7 days
High-dose ifosfamidei 2 14
Ifosfamide (2,800 mg m−2 day−1, IV over 5 days), uromitexan
(3 gm−2 day−1, IV over 6 days); total treatment duration: 7 days
High-dose melphalanj 2 4
Melphalan (200 mg/m2, PO on day 1); total treatment duration: 2 days
High-dose cyclophosphamidek 1 3
Cyclophosphamide (2 gm−2 day−1, on day 1+2), uromitexan
(2 g/m2, IV on days 1+2); total treatment duration: 3 days
Total treatment duration includes days for hydration and co-medication
a Small cell lung cancer
b sarcomas
c Hodgkin’s lymphoma (vincristine, bleomycine, procarbazine and prednisone were not part of home care treatment)
d Lymphoma
eMyeloma
f Sarcomas
g Refractory lymphomas
h Lymphoma, conditioning regimen before hematopoietic stem cell transplantation
i Recurrent sarcomas
j Myeloma, conditioning regimen before hematopoietic stem cell transplantation
k Hematopoietic stem cell mobilisation
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pleted by patients and relatives at the beginning and the end
of treatment. FLIC is a 22-item scaled questionnaire
covering seven dimensions of physical ability and the
psychosocial function (health status, social role, sociability,
emotional distress, pain, nausea, and suffering) Questions
were answered on a visual scale from 1 to 7 (total score
range, 22–154). When a question was omitted, a mean
score was attributed to the question, based on the patients
mean scores for the other questions. In addition, the WHO
performance status was assessed at the beginning and the
end of every home care treatment.
Satisfaction
A specific questionnaire on the satisfaction of patients and
relatives (Table 2) was designed by the Institute of Social
and Preventive Medicine of the University of Lausanne,
Switzerland, since no validated questionnaire was available.
The questionnaire is based on an Australian study [21, 22]
and documentation from the Centre of Documentation,
Research and Study in Health Economics ( http://www.
credes.net/). Most questions were “closed” but also “open-
ended” questions were included to gather more specific
information.
The questionnaires were given to the patient and his
main relative for completion at the end of every
treatment cycle at home. Results are shown as percen-
tages of the different possible responses for “closed”
questions and as a summary of the comments for “open-
ended” questions.
Costs
A cost evaluation was carried out in a subgroup of
patients who had received the same treatment at home
and during an inpatient hospitalisation. These patients
were selected after having received at least one cycle of
chemotherapy in the hospital. The first cycle of hospital-
based chemotherapy was not considered for cost evalu-
ation to avoid bias related to the initial clinical work-up.
Only the second or subsequent cycles, during which the
patient received only the chemotherapy, were considered
for cost evaluation.
The inpatient costs for nurses and administrative
employees were calculated on the basis of the annual
salary, work load, and number of days spent by the patient
in the hospital. The physician’s cost was based on the time
spent for a patient (clinical examination and administrative
work) and the monthly salary assuming a 60-h week
schedule. Hospital catering and meal and linen charges
were calculated from operating charges. Blood tests and
radiological exams were valued according to the detailed
account per patient and supplier. Other equipment was
charged according to the official catalogue price. Structural
charges including administrative hospital charges, medical
logistics, and building and equipment charges were esti-
mated as 45% of direct costs.
Costs for home care included nursing and medical staff
employed at the patients’ home and calculated based on the
time spent with the patients and monthly salaries. Patients’
expenses for meal and linen were not included. Home
transportation was charged at a rate of €0.41/km, plus the
salary costs for nurse and physician. Blood tests, consum-
ables, and drugs were calculated similarly to inpatient
treatment. No structural charges were considered for home
treatment. The Wilcoxon signed rank test was used for
comparison of means.
Results
Patient demographics
Between November 1998 and April 2001, 111 patients were
eligible to receive one of the studied chemotherapy
regimens (Table 1). Twenty-three patients (20.7%) fulfilled
all inclusion criteria, and 17 patients (74%) were enrolled in
the study. Six patients refused participation. Eight patients
were female and nine were male, with a median age of
48 years (range, 20–70 years). The relatives caring for the
patients were his wife (seven cases), her husband and
children (three cases), her husband alone (two cases), the
children and other relatives (two cases), the children and a
relative with professional healthcare experience (one case),
Table 2 Questionnaires on satisfaction of patients and relatives
Patient questions
1. Are you satisfied with your care at home?
2. If this experience were to start again, what would you choose?
3. What were the advantages of home treatment for you?
4. What were the disadvantages of home treatment for you?
5. Did you worry during home treatment?
6. Did you fear at any time that you might not obtain rapid,
appropriate care?
Relative questions
1. Are you in favor of home treatment after participation
in the program?
2. If this experience were to start again, what would you choose?
3. What were the advantages of home treatment for you?
4. What were the disadvantages of home treatment for you?
5. Did you worry during the home treatment?
6. Did you fear at any time that you might not obtain rapid,
appropriate care?
7. Do you have specific remarks concerning nursing care?
8. Do you have specific remarks concerning medical care?
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her husband and mother-in-law (one case), or the mother
(one case).
Treatments
In total, the study included 46 home-based treatments as the
majority of patients received multiple cycles of chemother-
apy (median, 3 cycles/patient; range, 1–10 cycles/patient;
Table 1). A subgroup of seven patients, representing a total
of 37 chemotherapy cycles, received the same chemother-
apy regimen at home and in the inpatient setting. These
patients were selected by the fact that they had already been
treated in the hospital and accepted to have their next
treatment at home.
Feasibility
Three planned visits/day (one by the physician and two by
the nurse) accounted for 621 visits during the 46 treatment
cycles representing 207 days of home care treatment.
Technical problems with the pump required 32 additional
home visits (median, 1 visit/cycle; range, 0–4 visits/cycle).
Most of the additional visits were needed at the beginning
of the study.
The main technical problem was pump failure due to air
bubbles that was resolved by flushing the tube (21 cases).
Partial disconnection at the exit channel occurred in nine
cases, and in two cases, the needle was disconnected from
the port of the catheter. These minor problems were easily
solved at the patients’ home. Two major pump failures
were reported resulting in one overnight hospitalisation
and a 4-day hospitalisation, respectively.
Safety
Medical complications occurred in three patients; one
experienced a heart failure (grade 3), one an angina attack
(grade 3), and one an allergic reaction to BCNU (grade 2).
The complications were treated at home, and no hospital-
isation was necessary. One patient was diagnosed with
anemia by routine testing and received transfusions in the
hospital outpatient unit. Nausea and vomiting, mainly
grades 1 and 2, occurred during 36% of chemotherapy
cycles and were controlled at home. No patients or relatives
asked for hospitalisation during home care. Eight un-
planned hospital admissions following the home care
period occurred, five for febrile neutropenia, two for fever
without documented infection, and one for pneumonia.
Quality of life
In total, 73 out of 92 (79%) FLIC questionnaires given to
the patients were completed and returned. Mean FLIC score
was 115.5±20.8 on day 1 of treatment (37 questionnaires)
and remained stable until the last day of treatment 114.8±
21.1 (36 questionnaires; Table 3). FLIC scores during home
care and inpatient treatment could be compared for five
patients (eight questionnaires, 37 chemotherapy cycles)
treated in both settings (Table 3). Neither the FLIC score
nor the seven FLIC categories differed significantly
between home care and inpatient treatment.
WHO performance status on day 1 was zero for 50% of
patients. During chemotherapy, the score remained stable at
zero in 28% of patients and increased to one or two in 65%
and 27% of patients, respectively.
Satisfaction of patients and relatives
Patients returned 32 questionnaires on 46 treatment
cycles (70%). They were either very satisfied with home
care (31 cases) or satisfied (one case). None of them
preferred the inpatient setting for the next chemotherapy
cycles. Thirty-eight percent stated a preference for home
care treatment, and the others had no declared preference
for the setting of their next chemotherapy cycles. Patient-
reported benefits of home care treatment included a
higher comfort level (100%), freedom and possibility to
organise their own time (94%), and the reassurance and
comfort of having a relative present (88%).
Most patients were not concerned about the absence of a
nurse (78%) and did not record anxiety (87%) during home
care treatment. Main patient-reported disadvantages of
home care were feelings of being dependent on their
relatives (19%) and/or being a burden (6%). Accordingly,
concerns mainly referred to the possibility that relatives
might be affected or distressed by chemotherapy side
effects. Other concerns included potential technical problems
of the pump and side effects of chemotherapy.
The relatives returned 29 questionnaires (63%). All were
in favor of home care, and most relatives (97%) preferred
home care for the next treatment; one relative did not
answer this specific question. Relatives stated better
tolerance (i.e., fewer side effects, less distress; 90%) and
less asthenia (48%) as advantages of home care. Other
remarks included “being more useful to the patient,” “being
more autonomous,” “being together,” and “more freedom.”
The main concerns were fear due to the presence of
Table 3 Comparison of FLIC scores for home care and hospitalised
patients
Home care, mean±SD
(n=17)
Inpatient, mean±SD
(n=5)
Day 1 115.5±14.2 117.2±20.1
End of treatment 114.8±21.1 113.2±25.8
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strangers at home (nurse, physician; 16%), request for
continuous presence as patients were not allowed to be
alone for more than one hour (14%), anxiety and fatigue
(14%), and lack of freedom for leisure and holidays (14%).
One relative did not know how to cope with patient’s
sadness. Twenty-one percent of relatives felt uncomfortable
about the absence of professional medical staff during the
treatment. Comments about the level and professionalism
of nursing and medical care were all positive.
Cost evaluation
Treatment costs were evaluated in a subgroup of seven
patients who received the same chemotherapy regimen at
home and during an inpatient hospitalisation. The treat-
ments were standard ICE in three patients, BEACOPP in
two patients and high-dose ifosfamide or VAD in one
patient each.
The mean daily difference in direct costs for home care
and inpatient hospitalisation was €198±61, a 32% benefit
in favor of home care (Table 4). Even if costs shifted to the
patients and relatives (catering, linen) were taken into
account, the balance remained beneficial. Inclusion of
overhead costs in the hospital setting increased the cost–
benefit of home care to 53%. The detailed evaluation of
daily costs demonstrated cost reductions of 77% for nursing
and 64% for paraclinical test costs if patients were treated at
home (Table 4). Costs for drugs and consumables did not
differ. Charges for catering in the hospital were balanced by
transportation costs associated with home care.
Discussion
This study demonstrates the feasibility and safety of home
care to administer intensive chemotherapies that are
currently recommended to be administered in an inpatient
facility. Preference of patients and caring relatives as well
as cost estimations are in favor of home care. Quality of life
of patients and caring relatives were not affected during the
treatment cycles examined.
Our results are in line with studies in pediatric oncology
patients demonstrating that home care was perceived as less
stressful than hospital care, had less impact on family life,
and increased parent’s involvement in their child’s treat-
ment [11, 13, 23, 24]. Home care was also preferred by
73% of 40 evaluated adult oncology patients. However, as
treatment in this study had to be administered by a
professional, preference for treatment location was depen-
dent on the waiting time for treatment.
Higher comfort levels and reassurance of having a
relative present were major determinants for high satisfac-
tion with home care. Concerns on the absence of
knowledgeable professionals in case of side effects as
reported in other studies [18] might have been overcome by
the frequent, scheduled visits of health-care professionals
and were mainly reported by relatives but not patients. Use
of a portable, programmable pump provided complete
autonomy to patients and enhanced satisfaction. Involve-
ment of relatives improved their understanding of disease
and treatment modalities and made them feel a help to the
patient. Conversely, the main concern of patients with home
care treatment referred to the feeling of being a burden to
their relatives.
All events reported during home treatment with the
exception of one blood transfusion due to anemia could be
controlled at home. These findings confirm former studies
reporting the safety of home care and showing reductions in
the length of hospitalisation and the risk of infections
compared to inpatient treatment [7, 8, 10]. Better oral
nutrition and better adaptation to the bacterial flora at home
are two possible explanations for lower infection frequen-
cies observed during home care [18]. However, pooled
statistics of studies comparing protective isolation (PI) with
standard hospital care suggest an infection-preventive effect
of PI although no benefit in mortality has been shown [25].
Cost effectiveness of home care programs is mainly
dependent on the equipment required for treatment admin-
istration and the involvement of health care professionals
during treatment. In our study, home care resulted in 53%
lower costs compared to the costs for providing the same
therapy in an inpatient setting. The main reason for the
Cost factor Home care (€, mean±SD) Inpatient care (€, mean±SD)
Physicians 21±3 19±2
Nurses and other care givers 65±10 216±14
Paraclinical tests 25±10 70±35
Drugs, equipment 255±108 249±95
Catering 0 63±4
Transportation 55±34 0
Mean daily direct cost* 420±101* 618±123*
Mean daily direct cost including overheads 420±120 896±165
Table 4 Cost evaluation (n=7
patients)
*p=0.009
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observed cost reduction is the use of an automated pump
reducing the involvement of nursing and paraclinical
tests. This finding is in line with nine out of 13
published studies showing lower mean direct costs for
home care compared to hospital care [16]. Detailed
assessment of another randomised, controlled study also
demonstrated lower total costs of home care; however,
marginal costs in that study were lower in the hospital
setting [17]. In order to improve our estimation of cost
effectiveness, a larger patient sample size and the use of
specific models would be required.
Conclusion
Following advances in prognosis and therapy of cancer,
increasing emphasis is being placed on the psychosocial
aspects of cancer care. This includes attempts to treat
patients in their home environment.
This study, although limited by size, clearly demon-
strates that home care is a valuable alternative for oncology
patients, even for the administration of intensive chemo-
therapies. Further studies should be designed to better
delineate the full potential of this kind of approach, as
health care resources become increasingly limited, and new
ways of taking care of patients are needed.
Acknowledgements This study was partially funded by a grant from
the University Hospital
Conflict of interest statement The authors have no financial or
personal relation with other people or organisations that could have
inappropriately influenced the planning, conduct or analysis of this
study.
References
1. Caplan GA et al (1999) Hospital in the home: a randomised
controlled trial. Med J Aust 170(4):156–160
2. Richards SH et al (1998) Randomised controlled trial comparing
effectiveness and acceptability of an early discharge, hospital at
home scheme with acute hospital care. BMJ 316(7147):1796–
1801 [erratum appears in BMJ 1998 Sep;317(7161):786]
3. Santos-Eggimann B et al (2001) Heart failure and community-
acquired pneumonia: cases for home hospital? Int J Qual Health
Care 13(4):301–307
4. Shepperd S et al (2008) Admission avoidance hospital at home.
Cochrane Database Syst Rev 4:CD007491
5. Shepperd S et al (1998) Randomised controlled trial comparing
hospital at home care with inpatient hospital care. II: cost
minimisation analysis. BMJ 316(7147):1791–1796
6. Wilson A et al (1999) Randomised controlled trial of effectiveness
of Leicester hospital at home scheme compared with hospital care.
BMJ 319(7224):1542–1546 [see comment]
7. Fernandez-Aviles F et al (2006) Case-control comparison of at-
home to total hospital care for autologous stem-cell transplanta-
tion for hematologic malignancies. J Clin Oncol 24(30):4855–
4861
8. Meisenberg BR et al (1997) Outpatient high-dose chemotherapy
with autologous stem-cell rescue for hematologic and nonhemato-
logic malignancies. J Clin Oncol 15(1):11–17
9. Svahn BM et al (2008) Case-control comparison of at-home
and hospital care for allogeneic hematopoietic stem-cell
transplantation: the role of oral nutrition. Transplantation 85
(7):1000–1007
10. Westermann AM et al (1999) At home management of aplastic
phase following high-dose chemotherapy with stem-cell rescue for
hematological and non-hematological malignancies. Ann Oncol
10(5):511–517
11. Hooker L, Kohler J (1999) Safety, efficacy, and acceptability of
home intravenous therapy administered by parents of pediatric
oncology patients. Med Pediatr Oncol 32(6):421–426
12. Jayabose S et al (1992) Home chemotherapy for children with
cancer. Cancer 69(2):574–579
13. Stevens B et al (2006) Children receiving chemotherapy at home:
perceptions of children and parents. J Pediatr Oncol Nurs 23
(5):276–285
14. King MT et al (2000) Home or hospital? An evaluation of the
costs, preferences, and outcomes of domiciliary chemotherapy. Int
J Health Serv 30(3):557–579
15. Vinciguerra V et al (1986) A comparative assessment of home
versus hospital comprehensive treatment for advanced cancer
patients. J Clin Oncol 4(10):1521–1528
16. Hirtzlin I, Préaubert-Hayes N (2005) In-hospital and at-home
cancer chemotherapy: a comparison of costs and organisation of
care. H.E.a.P.H.D., Haute Autorité de Santé, Paris, pp 1–9
17. Remonnay R et al (2002) Economic evaluation of antineoplasic
chemotherapy administered at home or in hospitals. Int J Technol
Assess Health Care 18(3):508–519
18. Kelly D et al (2004) Achieving change in the NHS: a study to
explore the feasibility of a home-based cancer chemotherapy
service. Int J Nurs Stud 41(2):215–224
19. Miller AB et al (1981) Reporting results of cancer treatment.
Cancer 47(1):207–214
20. Schipper H et al (1984) Measuring the quality of life of cancer
patients: the functional living index-cancer: development and
validation. J Clin Oncol 2(5):472–483
21. Dubois A, Santos-Eggimann B (2001) Evaluation of patients’
satisfaction with hospital-at-home care. Eval Health Prof 24
(1):84–98
22. Montalto M (1996) Patients’ and carers’ satisfaction with hospital-
in-the-home care. Int J Qual Health Care 8(3):243–251
23. Close P et al (1995) A prospective, controlled evaluation of
home chemotherapy for children with cancer. Pediatrics 95
(6):896–900
24. Stevens B et al (2006) Economics of home vs. hospital
breastfeeding support for newborns. J Adv Nurs 53(2):233–
243
25. van Tiel FH et al (2005) Home care versus hospital care of
patients with hematological malignancies and chemotherapy-
induced cytopenia. Ann Oncol 16(2):195–205
Support Care Cancer (2012) 20:575–581 581
